Latest Updates of Key Players in the Topical Veterinary Dermatology Market with Value Chain Analysis 2026
| Company | Headquarters | Latest Update |
| Zoetis Inc. | United States | In November 2025, Zoetis Inc. announced the acquisition of Veterinary Pathology Group (VPG), a leading veterinary diagnostic laboratory group with many locations across the UK and Ireland. |
| Boehringer Ingelheim Animal Health | United States | Boehringer Ingelheim is a leading research-driven biopharmaceutical company. |
| Elanco Animal Health Incorporated | United States | In July 2025, Elanco Animal Health Incorporated announced that Zenrelia had received approval from the European Commission. |
| Merck & Co., Inc. | United States | In June 2025, Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products issued a positive opinion for NUMELVI Tablets for Dogs. |
| Virbac S.A. | France | Virbac S.A. continues to hold a strong position in the worldwide veterinary dermatology. |
| Dechra Pharmaceuticals PLC | United Kingdom | In November 2025, Dechra announced its status as the novel Human-Animal Bond Certified Company. Dechra has made a key commitment to helping human-animal bond education for veterinary professionals. |
Value Chain Analysis: Topical Veterinary Dermatology Market
R&D:
- Research and Development (R&D) in veterinary pharmaceuticals is a severe, multidisciplinary, and prolonged process, often taking 5 to 10 years, designed to bring novel treatments, vaccines, and diagnostic tools to animal health
- Key Players: Boehringer Ingelheim International GmbH
Manufacturing Processes:
- These processes are severely controlled by Good Manufacturing Practices (GMP) and include granulation, formulation, mixing, sterilization, and packaging.
- Key Players: Merck & Co., Inc., and Virbac
Patient Services:
- Significant services involve targeted medication compounding, precise dispensing, client education on administration, and monitoring for adverse drug reactions.
- Key Players: Zoetis Inc., and Elanco Animal Health Incorporated
Market Growth Story
The global topical veterinary dermatology market size was estimated at USD 1.17 billion in 2025 and is predicted to increase from USD 1.24 billion in 2026 to approximately USD 2.15 billion by 2035, expanding at a CAGR of 6.25% from 2026 to 2035.
Recent Developments in the Topical Veterinary Dermatology Market
- In March 2025, Amgen and Kyowa Kirin Co., Ltd. announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).
- In December 2025, Alphyn Biologics, Inc., announced the close of its $25 million, twice-oversubscribed Series B financing. Proceeds will fund the Phase 2b global clinical trial of Alphyn's lead drug candidate, Zabalafin Hydrogel, for atopic dermatitis (AD), initiate a second Phase 2 clinical program for the treatment of the molluscum contagiosum virus (MCV), and expand the company's supply of drug raw material.
Want to manage your all healthcare reports and insights with ease and clarity? Checkout our Dashboard and Get Easy Access
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
